+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Leuprorelin Drugs Market by Indication (Endometriosis, Precocious Puberty, Prostate Cancer), Product Type (Depot Injection, Immediate Release Injection, Implant), Dosage, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Leuprorelin Drugs Market by Indication (Endometriosis, Precocious Puberty, Prostate Cancer), Product Type (Depot Injection, Immediate Release Injection, Implant), Dosage, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
New

Leuprorelin Drugs Market by Indication (Endometriosis, Precocious Puberty, Prostate Cancer), Product Type (Depot Injection, Immediate Release Injection, Implant), Dosage, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6146966
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Leuprorelin has emerged as a cornerstone in the management of hormone-dependent conditions, offering robust therapeutic benefits across gynecological, oncological, and pediatric endocrinology indications. This executive summary introduces the molecule’s significance in treating endometriosis, prostate cancer, uterine fibroids, and precocious puberty, underscoring its mechanism of action as a gonadotropin-releasing hormone agonist that modulates hormonal cycles to deliver sustained clinical outcomes. Recognizing the broad impact of leuprorelin therapies, investigators and industry strategists have focused on advancing delivery formats, refining dosing regimens, and navigating complex regulatory pathways to maximize patient benefit.

Furthermore, the introduction sets the context for exploring how patient preferences and healthcare infrastructure are converging to drive demand for varied presentation types, ranging from depot injections to implantable devices. It also outlines the challenges of balancing treatment efficacy with adherence considerations, particularly as newer patient cohorts seek less invasive, more flexible administration options. In addition, the summary frames the key report objectives: to highlight transformative market shifts, dissect the implications of recent U.S. tariff policies, and deliver actionable recommendations for industry stakeholders. Ultimately, this introduction lays a strategic foundation, orienting readers to the multifaceted landscape of leuprorelin innovation and its pivotal role in future therapeutic advancements.

Uncovering the Dynamic Shifts Transforming Leuprorelin Development Pathways and Delivery Technologies in a Rapidly Evolving Therapeutic Environment

The leuprorelin landscape is undergoing a period of rapid transformation driven by technological breakthroughs and shifting stakeholder expectations. Emerging formulation technologies are enabling extended-release profiles that enhance patient adherence while minimizing injection frequency. In parallel, digital health solutions are being integrated to track dosing schedules and patient outcomes, offering real-time insights that inform clinical decision making and promote personalized care. Moreover, advanced polymer-based implants are redefining sustained delivery, reducing the burden on healthcare providers and patients alike.

In addition to delivery innovations, regulatory agencies are showing increased receptivity to adaptive trial designs, fast-track approvals, and real-world evidence submissions that accelerate the introduction of next-generation leuprorelin products. Simultaneously, patient advocacy groups are amplifying the call for therapies that address quality-of-life concerns, prompting developers to explore novel peptide analogs and targeted combination regimens. Taken together, these transformative shifts are not only redefining competitive dynamics but also reshaping the strategic imperatives for companies seeking to establish leadership in the evolving leuprorelin market.

Analyzing How New United States Tariff Policies Will Influence Supply Chains Pricing Dynamics and Innovation for Leuprorelin Products in 2025

Recent changes to United States tariff policies are exerting a notable influence on the global leuprorelin supply chain and cost structure. By imposing additional duties on key active pharmaceutical ingredient imports and specialized packaging components, these regulations have introduced new considerations for sourcing strategies and distributor agreements. As a result, manufacturers are reevaluating their procurement networks, and some are pursuing localized production partnerships to mitigate exposure to fluctuating tariff schedules.

In the face of these policy shifts, commercial teams are reassessing pricing models to preserve margin integrity while maintaining patient access. Negotiations with payers and healthcare providers are increasingly focused on value-based contracting frameworks that align reimbursement with therapeutic outcomes. Furthermore, manufacturers are exploring vertically integrated supply solutions and strategic inventory buffers to safeguard against potential logistical disruptions. Collectively, these measures demonstrate how the evolving tariff landscape is prompting industry participants to adopt more agile, resilient approaches to ensure uninterrupted delivery of leuprorelin therapies to patients.

Revealing Key Market Segmentation Insights by Indication Product Type Dosage Distribution Channel and End User for Leuprorelin Therapies

A nuanced understanding of market segmentation illuminates distinct demand drivers across multiple axes of leuprorelin utilization. When examining therapeutic indications, the endometriosis segment reveals a bifurcation in treatment patterns: patients with mild to moderate disease often initiate therapy with one-month dosing to assess tolerability, while those in severe stages frequently transition to extended-release formulations for three- to six-month intervals. Within oncological use, metastatic prostate cancer requires sustained dosing to manage advanced disease progression, whereas non-metastatic cases may benefit from shorter-duration courses that balance recurrence prevention with quality-of-life considerations. In pediatric endocrinology, management of precocious puberty predominantly leverages monthly injections to closely monitor growth parameters.

Investigating product type further clarifies how depot injections dominate overall volume, especially in one- and three-month dosage formats, while immediate-release injections and implantable devices serve niche patient cohorts prioritizing rapid onset or ultra-long duration. Across dosage strata, the six-month regimen has gained traction in chronic indications, reflecting patient and provider appetite for reduced administration frequency. Distribution channel analysis highlights hospital pharmacies as primary access points for complex cases, whereas online pharmacies are expanding reach into underserved regions and retail pharmacies maintain their role in outpatient continuity of care. Evaluating end user environments underscores a growing shift toward home care settings, which offer convenience for stable patients and alleviate burden on clinic resources.

Highlighting Regional Nuances in Leuprorelin Adoption and Access Across the Americas Europe Middle East Africa and Asia Pacific Markets

Regional dynamics play a pivotal role in shaping leuprorelin adoption and market access. In the Americas, a mature healthcare infrastructure and established reimbursement frameworks underpin broad acceptance of advanced formulations, while collaborative initiatives among academic centers and industry are fostering rapid uptake of next-generation delivery technologies. Conversely, across Europe, Middle East and Africa, stakeholders navigate a heterogeneous regulatory environment that encompasses harmonized directives in some regions alongside localized approval pathways in others. This complexity has spurred partnerships between global manufacturers and regional distributors to streamline market entry and expand patient access.

Within the Asia-Pacific region, escalating healthcare investments and growing awareness of hormone-dependent conditions are fueling demand for both branded and generic leuprorelin offerings. Governments are enhancing public sector procurement capabilities, and private payers are incorporating value-based models that incentivize long-term treatment adherence. At the same time, emerging economies in the region are witnessing capacity expansions in contract manufacturing, enabling more cost-competitive supply solutions. Taken together, these regional nuances highlight the importance of tailored strategies that align with local regulatory, reimbursement, and infrastructure realities.

Profiling Leading Pharmaceutical Innovators Shaping the Competitive Landscape and Driving Strategic Collaborations in the Leuprorelin Market

The competitive landscape of the leuprorelin market is defined by a blend of legacy pharmaceutical titans and emerging biotech innovators. Established entities continue to refine their portfolios through lifecycle management, introducing novel sustained-release implants and combination regimens that differentiate their offerings. Simultaneously, specialty pharmaceutical companies are leveraging scientific partnerships to advance peptide optimization and targeted delivery platforms, seeking to carve out niches in high-value segments such as metastatic oncology and pediatric endocrinology.

In addition, strategic alliances have become a key mechanism for accelerating late-stage development and expanding geographic reach. Licensing agreements with regional manufacturers enable global players to overcome local market barriers, while co-development pacts with contract development organizations streamline formulation analytics and scale-up. Mergers and acquisitions remain an important lever, enabling companies to bolster their pipeline depth and enhance manufacturing capabilities. Together, these strategic maneuvers underscore the dynamic interplay between innovation, collaboration, and competitive positioning in the global leuprorelin arena.

Delivering Actionable Strategic Recommendations to Advance Market Competitiveness Optimize Patient Access and Drive Sustainable Growth for Leuprorelin

To navigate the evolving leuprorelin landscape and secure sustainable growth, industry leaders should prioritize diversification of manufacturing footprints to mitigate supply chain vulnerabilities. Investing in advanced drug delivery technologies can unlock new patient cohorts and differentiate portfolios, while integrating digital adherence solutions enhances real-world engagement and outcome measurement. Engaging payers early in the development process to co-design value frameworks will facilitate smoother reimbursement pathways and foster outcome-based contracts that align incentives across stakeholders.

Moreover, forging strategic partnerships with biotechnology firms and academic centers can accelerate innovation and expand capabilities in peptide engineering and implant design. Expanding home care service offerings and virtual patient support programs will meet the growing demand for decentralized treatment models. Finally, proactive scenario planning for policy shifts, including tariff adjustments and evolving regulatory requirements, will enable companies to respond with agility, ensuring uninterrupted patient access and preserving competitive advantage.

Detailing Rigorous Mixed Method Research Approaches and Data Validation Protocols Underpinning the Comprehensive Analysis of the Leuprorelin Market

The insights presented in this report are grounded in a rigorous mixed-method research framework. Primary data was collected through in-depth interviews with key opinion leaders, including endocrinologists, oncologists, and supply chain executives, to capture firsthand perspectives on clinical practice, formulation preferences, and emerging obstacles. Complementary quantitative surveys were administered to procurement specialists and pharmacy directors, providing a robust dataset on channel dynamics and end user behavior.

Secondary research encompassed analysis of peer-reviewed journals, regulatory filings, clinical trial registries, and patent landscapes to contextualize technological advancements and approval trends. Data triangulation was performed by cross-referencing multiple sources to validate findings and ensure consistency. Additionally, expert panels convened to challenge assumptions, refine analytical models, and stress-test strategic scenarios. This comprehensive approach underpins the report’s credibility, delivering a balanced and deeply informed perspective on the current and future state of the leuprorelin market.

Distilling Key Takeaways on Market Dynamics Competitive Forces and Strategic Imperatives to Navigate the Future of Leuprorelin Therapeutics

The global leuprorelin therapeutic landscape is characterized by rapid innovation, complex regulatory shifts, and evolving payer expectations. Advances in extended-release formulations and implantable technologies are transforming patient care, while tariff adjustments are prompting supply chain realignments that require strategic agility. Segmentation insights reveal diverse utilization patterns across indications, dosage schedules, distribution channels, and end user environments, underscoring the necessity of nuanced commercial strategies.

Regional disparities in reimbursement structures and manufacturing capacity highlight the importance of localized market entry tactics. Competitive dynamics are intensifying as established pharmaceutical leaders and nimble biotech companies vie for position, driving collaboration, licensing, and acquisition activity. In summary, stakeholders who embrace patient-centric innovation, foster strategic partnerships, and proactively adapt to policy and market shifts will be best positioned to lead in the next generation of leuprorelin therapeutics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Endometriosis
      • Mild To Moderate Stage
      • Severe Stage
    • Precocious Puberty
    • Prostate Cancer
      • Metastatic Stage
      • Non Metastatic Stage
    • Uterine Fibroids
  • Product Type
    • Depot Injection
      • One Month Dosage
      • Six Month Dosage
      • Three Month Dosage
    • Immediate Release Injection
    • Implant
  • Dosage
    • One Month Dosage
    • Six Month Dosage
    • Three Month Dosage
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User
    • Clinics
    • Home Care Settings
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Pfizer Inc.
  • Novartis AG
  • Ferring Pharmaceuticals A/S
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Intas Pharmaceuticals Ltd.
  • Hunan Xiangzhong Pharmaceutical Co., Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Impact of global patent expirations on generic leuprorelin pricing and market share dynamics
5.2. Economic implications of biosimilar leuprorelin entry across European oncology treatment pathways
5.3. Emerging preference for extended-release subcutaneous leuprorelin implants in prostate cancer management
5.4. Rising adoption of digital adherence monitoring solutions integrated with leuprorelin therapy in telehealth
5.5. Real-world comparative analysis of three-month versus monthly leuprorelin depot formulations on patient adherence
5.6. Expansion of leuprorelin approvals in Asia Pacific driven by growing hormone therapy demand and reimbursement reforms
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Leuprorelin Drugs Market, by Indication
8.1. Introduction
8.2. Endometriosis
8.2.1. Mild To Moderate Stage
8.2.2. Severe Stage
8.3. Precocious Puberty
8.4. Prostate Cancer
8.4.1. Metastatic Stage
8.4.2. Non Metastatic Stage
8.5. Uterine Fibroids
9. Leuprorelin Drugs Market, by Product Type
9.1. Introduction
9.2. Depot Injection
9.2.1. One Month Dosage
9.2.2. Six Month Dosage
9.2.3. Three Month Dosage
9.3. Immediate Release Injection
9.4. Implant
10. Leuprorelin Drugs Market, by Dosage
10.1. Introduction
10.2. One Month Dosage
10.3. Six Month Dosage
10.4. Three Month Dosage
11. Leuprorelin Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Leuprorelin Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care Settings
12.4. Hospitals
13. Americas Leuprorelin Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Leuprorelin Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Leuprorelin Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Teva Pharmaceutical Industries Ltd.
16.3.3. Viatris Inc.
16.3.4. Pfizer Inc.
16.3.5. Novartis AG
16.3.6. Ferring Pharmaceuticals A/S
16.3.7. Sun Pharmaceutical Industries Ltd.
16.3.8. Lupin Limited
16.3.9. Intas Pharmaceuticals Ltd.
16.3.10. Hunan Xiangzhong Pharmaceutical Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. LEUPRORELIN DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. LEUPRORELIN DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. LEUPRORELIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. LEUPRORELIN DRUGS MARKET: RESEARCHAI
FIGURE 26. LEUPRORELIN DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. LEUPRORELIN DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. LEUPRORELIN DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LEUPRORELIN DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY MILD TO MODERATE STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY MILD TO MODERATE STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY SEVERE STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY SEVERE STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY PRECOCIOUS PUBERTY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY PRECOCIOUS PUBERTY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY METASTATIC STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY METASTATIC STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY NON METASTATIC STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY NON METASTATIC STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY UTERINE FIBROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY UTERINE FIBROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY ONE MONTH DOSAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY ONE MONTH DOSAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY SIX MONTH DOSAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY SIX MONTH DOSAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY THREE MONTH DOSAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY THREE MONTH DOSAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY IMMEDIATE RELEASE INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY IMPLANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY IMPLANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY ONE MONTH DOSAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY ONE MONTH DOSAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY SIX MONTH DOSAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY SIX MONTH DOSAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY THREE MONTH DOSAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY THREE MONTH DOSAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL LEUPRORELIN DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES LEUPRORELIN DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 107. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 108. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 109. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 110. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 111. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 112. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 113. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 114. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 115. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 116. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 117. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 118. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 119. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. CANADA LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 124. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 125. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 128. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 129. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 132. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 133. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 134. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 135. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. MEXICO LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 210. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 211. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 214. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 215. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 216. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 217. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. GERMANY LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 226. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 227. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 228. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 229. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 230. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 231. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 232. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 233. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. FRANCE LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 254. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 255. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 256. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 257. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 258. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 259. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 260. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 261. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 262. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 263. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 264. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 265. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. ITALY LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 272. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 273. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 274. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 275. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 276. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 277. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 278. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 279. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 280. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 281. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. SPAIN LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. SAUDI ARABIA LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 322. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 326. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 328. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 329. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 330. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 331. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 332. SOUTH AFRICA LEUPRORELIN DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 333. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 334. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 335. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2018-2024 (USD MILLION)
TABLE 336. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY ENDOMETRIOSIS, 2025-2030 (USD MILLION)
TABLE 337. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 338. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 339. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 340. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 341. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2018-2024 (USD MILLION)
TABLE 342. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY DEPOT INJECTION, 2025-2030 (USD MILLION)
TABLE 343. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
TABLE 344. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY DOSAGE, 2025-2030 (USD MILLION)
TABLE 345. DENMARK LEUPRORELIN DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 346. DENMARK LEUPRORELIN

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Leuprorelin Drugs market report include:
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Pfizer Inc.
  • Novartis AG
  • Ferring Pharmaceuticals A/S
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Limited
  • Intas Pharmaceuticals Ltd.
  • Hunan Xiangzhong Pharmaceutical Co., Ltd.

Related Topics

Related Reports

Fadrozole Market by Indication (Breast Cancer, Endometriosis, Ovary Cancer), Route Of Administration (Injectable, Intravenous, Oral), Dosage Form, Distribution Channel, End User, Strength - Global Forecast 2025-2030 - Product Image

Fadrozole Market by Indication (Breast Cancer, Endometriosis, Ovary Cancer), Route Of Administration (Injectable, Intravenous, Oral), Dosage Form, Distribution Channel, End User, Strength - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 - Product Image

Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030

  • Report
  • 600 Pages
  • Global
From
Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Indication (Diabetic Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), Product (Aflibercept, Bevacizumab, Brolucizumab), Type, End Use, Distribution Channel, Dosage Form - Global Forecast 2025-2030 - Product Image

Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market by Indication (Diabetic Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), Product (Aflibercept, Bevacizumab, Brolucizumab), Type, End Use, Distribution Channel, Dosage Form - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Aß Monoclonal Antibody Drug Market by Route Of Administration, Therapeutic Line, Molecule Type, Payer Type, Indication Stage, Distribution Channel, Dosage Frequency - Global Forecast 2025-2030 - Product Image

Aß Monoclonal Antibody Drug Market by Route Of Administration, Therapeutic Line, Molecule Type, Payer Type, Indication Stage, Distribution Channel, Dosage Frequency - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Generic Oncology Drugs Market by Drug Type (Biologics, Small Molecule), Indication (Breast Cancer, Colorectal Cancer, Leukemia), Distribution Channel, Route Of Administration, Therapy Line, Mechanism Of Action, Formulation - Global Forecast 2025-2030 - Product Image

Generic Oncology Drugs Market by Drug Type (Biologics, Small Molecule), Indication (Breast Cancer, Colorectal Cancer, Leukemia), Distribution Channel, Route Of Administration, Therapy Line, Mechanism Of Action, Formulation - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.